Sökning: WFRF:(Abrahamsson Jonas 1954) >
Optimal treatment i...
Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature.
-
Abildgaard, Lotte (författare)
-
Ellebaek, Eva (författare)
-
- Gustafsson, Göran (författare)
- Karolinska Institutet
-
visa fler...
-
- Abrahamsson, Jonas, 1954 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
-
Hovi, Liisa (författare)
-
Jonmundsson, Gudmundur (författare)
-
Zeller, Bernward (författare)
-
Hasle, Henrik (författare)
-
visa färre...
-
(creator_code:org_t)
- 2006-03-04
- 2006
- Engelska.
-
Ingår i: Annals of hematology. - : Springer Science and Business Media LLC. - 0939-5555 .- 1432-0584. ; 85:5, s. 275-80
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Children with Down syndrome (DS) and myeloid leukaemia have a significantly higher survival rate than other children, but they also experience considerable treatment-related toxicity. We analysed data on 56 children with DS who were treated on the Nordic Society for Paediatric Haematology and Oncology-acute myeloid leukaemia (NOPHO-AML)88 and NOPHO-AML93 protocols and reviewed the literature. In the dose-intensive NOPHO-AML88 protocol, 8 out of 15 patients (53%) experienced an event. In the less dose-intensive NOPHO-AML93 protocol, 7 out of 41 patients (17%) had an event. Therapy was reduced in 29 patients (52%) with in average 75% and 67% of the scheduled dose of anthracycline and cytarabine, respectively. Treatment-related death occurred in seven who all received full treatment. Relapse and resistant disease occurred at a similar rate in those receiving full and reduced treatment. Review of major series of myeloid leukaemia of DS showed no clear relationship between dose and survival; however, it appears that both a reduction in treatment dose and a less intensively timed treatment regimen improved the outcome. Further studies are needed to define the optimal regimen for treating myeloid leukaemia of DS.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Pediatrik (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Pediatrics (hsv//eng)
Nyckelord
- Anthracyclines
- administration & dosage
- adverse effects
- Antineoplastic Combined Chemotherapy Protocols
- administration & dosage
- adverse effects
- Child
- Preschool
- Cytarabine
- administration & dosage
- adverse effects
- Disease-Free Survival
- Down Syndrome
- complications
- mortality
- Humans
- Leukemia
- Myeloid
- complications
- drug therapy
- mortality
- Male
- Remission Induction
- Retrospective Studies
- Survival Rate
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas